Market Cap 1.42B
Revenue (ttm) 272.30M
Net Income (ttm) -5.14M
EPS (ttm) N/A
PE Ratio 84.96
Forward PE 78.99
Profit Margin -1.89%
Debt to Equity Ratio 4.67
Volume 5,405,500
Avg Vol 858,134
Day's Range N/A - N/A
Shares Out 37.27M
Stochastic %K 2%
Beta 0.34
Analysts Strong Sell
Price Target $66.71

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
Finnish_boy
Finnish_boy May. 13 at 10:11 AM
$HROW Shit happens. They should have been more strict about pricing already in Q1. Crazy buy right now. Bottom $25-29, no idea when/where. Some people can be worried bc they have no idea what is ahead and why the problems were meaningless.
0 · Reply
Finnish_boy
Finnish_boy May. 13 at 9:08 AM
$HROW $30->$200 is 550% in 4 years.
0 · Reply
Finnish_boy
Finnish_boy May. 13 at 9:07 AM
$HROW My PT $100 2027 and PT $200 by the year end of 2029. $400-500 PTs are bs imo. Revenue growth and operational leverage huge but not crazy.
0 · Reply
Finnish_boy
Finnish_boy May. 13 at 6:38 AM
$HROW Amazing write-up. Brilliant. Read it and realize that even mgt keeps missing guidances, you will win tons of money next years. https://mvcinvesting.substack.com/p/harrow-hrow-q1-2026-earnings-review
0 · Reply
Finnish_boy
Finnish_boy May. 13 at 6:37 AM
$HROW At the weekly level of 200 MA ($25.5), I think there will be a turnaround like at the beginning of 2024 and then we will see in a year that it was a good place to buy again. Of course, anything can happen, but I have a very strong feeling that the stock will hit $100 within 1-2 years.
1 · Reply
S144
S144 May. 13 at 5:06 AM
$HROW At $29 it is a real bargain. I would say: it is a buy. Let's say: if it recovers fully after Q2 results one could gain +38% in just 3 months.
1 · Reply
Dbarnyard
Dbarnyard May. 13 at 2:22 AM
$HROW Some people made fun of me when I suggested that the stock price of $ETON would overtake HROW. Perhaps the market caps will cross soon as well. Then those people can apologize to me 😄
0 · Reply
bitdix66
bitdix66 May. 12 at 9:54 PM
$HROW If you've been a shareholder for awhile (since 2021 myself) you know just how volatile this stock is. I've become "numb" to these massive drawdowns. I am still long, but... I do not believe they will achieve the $250 million quarter in Q4 2027. I think it is more reasonable in 2030, and anytime before then is a bonus. ---2030 @ $1 billion--- $1B revenue * 25% Net Income = $250M profit * 15 P/E = $3.75B MC / 40 million shares = $93/sh That's a 3x from here in 4 years (30% IRR). They may also have higher net margins than 25%. Pat Sullivan (Chief Commercial Officer) who was on the call also has his comp package tied to the $230M in branded segment per quarter. Source: https://investors.harrow.com/static-files/bdf5e5d6-0728-4a1d-9302-e70bc9dfeb14 Mark and Andrew have PSUs if the stock reaches $100. These guys do not want to fail. They have consistently pivoted and changed course to success over the past 5 years I've been following these guys (anyone remember Visionology and MAQ-100?). But they need to figure out the pricing strategy for Vevye.
5 · Reply
SelfMafia
SelfMafia May. 12 at 9:03 PM
$HROW Jonah Lupton Special
0 · Reply
Hpad06
Hpad06 May. 12 at 8:42 PM
$HROW for this growth, no reason to panic, buy the dip
1 · Reply
Latest News on HROW
Harrow Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 23 hours ago

Harrow Earnings Call Transcript: Q1 2026


Harrow reports Q1 EPS (74c) vs. (50c) last year

2026-05-11T20:41:15.000Z - 1 day ago

Harrow reports Q1 EPS (74c) vs. (50c) last year


Harrow Announces First Quarter 2026 Financial Results

May 11, 2026, 4:05 PM EDT - 1 day ago

Harrow Announces First Quarter 2026 Financial Results


Harrow announces issuance of J-Code for Iopidine 1%

2026-04-16T11:57:26.000Z - 26 days ago

Harrow announces issuance of J-Code for Iopidine 1%


Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

Apr 16, 2026, 7:00 AM EDT - 27 days ago

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%


Harrow selects LogiCare3PL as distribution partner

2026-04-14T14:35:13.000Z - 4 weeks ago

Harrow selects LogiCare3PL as distribution partner


LogiCare3PL Selected as Distribution Partner by Harrow

Apr 14, 2026, 10:30 AM EDT - 4 weeks ago

LogiCare3PL Selected as Distribution Partner by Harrow


Harrow management to meet virtually with BTIG

2026-04-09T20:33:07.000Z - 4 weeks ago

Harrow management to meet virtually with BTIG


Harrow management to meet virtually with BTIG

2026-04-09T20:25:15.000Z - 4 weeks ago

Harrow management to meet virtually with BTIG


Harrow price target lowered to $65 from $74 at B. Riley

2026-04-07T13:01:36.000Z - 5 weeks ago

Harrow price target lowered to $65 from $74 at B. Riley


Harrow price target lowered to $65 from $74 at B. Riley

2026-04-07T12:28:56.000Z - 5 weeks ago

Harrow price target lowered to $65 from $74 at B. Riley


Harrow Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 8:40 AM EDT - 2 months ago

Harrow Transcript: Leerink Global Healthcare Conference 2026


Harrow price target lowered to $60 from $70 at Lake Street

2026-03-04T13:45:34.000Z - 2 months ago

Harrow price target lowered to $60 from $70 at Lake Street


Harrow price target lowered to $62 from $66 at Ladenburg

2026-03-04T12:41:07.000Z - 2 months ago

Harrow price target lowered to $62 from $66 at Ladenburg


Harrow price target raised to $70 from $69 at H.C. Wainwright

2026-03-04T11:12:28.000Z - 2 months ago

Harrow price target raised to $70 from $69 at H.C. Wainwright


Harrow Earnings Call Transcript: Q4 2025

Mar 3, 2026, 8:00 AM EST - 2 months ago

Harrow Earnings Call Transcript: Q4 2025


Harrow sees FY26 revenue $350M-$365M, consensus $386.39M

2026-03-02T21:39:03.000Z - 2 months ago

Harrow sees FY26 revenue $350M-$365M, consensus $386.39M


Harrow reports Q4 EPS 17c vs. 24c last year

2026-03-02T21:26:50.000Z - 2 months ago

Harrow reports Q4 EPS 17c vs. 24c last year


Harrow reports Q4 EPS 17c vs. 24c last year

2026-03-02T21:25:40.000Z - 2 months ago

Harrow reports Q4 EPS 17c vs. 24c last year


Harrow  sees FY26 revenue $350M-$365M, cosnensus $386.39M

2026-03-02T21:24:12.000Z - 2 months ago

Harrow sees FY26 revenue $350M-$365M, cosnensus $386.39M


Harrow to Present at Two Investor Conferences in December

Nov 24, 2025, 7:00 AM EST - 6 months ago

Harrow to Present at Two Investor Conferences in December


Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Nov 18, 2025, 7:00 AM EST - 6 months ago

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals


Harrow Earnings Call Transcript: Q3 2025

Nov 11, 2025, 8:00 AM EST - 6 months ago

Harrow Earnings Call Transcript: Q3 2025


Harrow Announces Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 6 months ago

Harrow Announces Third Quarter 2025 Financial Results


ImprimisRx Announces Leadership Changes

Oct 6, 2025, 7:00 AM EDT - 7 months ago

ImprimisRx Announces Leadership Changes


Harrow Transcript: Investor Day 2025

Sep 26, 2025, 11:30 AM EDT - 8 months ago

Harrow Transcript: Investor Day 2025


Harrow to Acquire Melt Pharmaceuticals

Sep 26, 2025, 7:00 AM EDT - 8 months ago

Harrow to Acquire Melt Pharmaceuticals


Harrow Launches Harrow Access for All (HAFA)

Sep 25, 2025, 4:05 PM EDT - 8 months ago

Harrow Launches Harrow Access for All (HAFA)


Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 15, 2025, 7:00 AM EDT - 8 months ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day


Harrow Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 9 months ago

Harrow Earnings Call Transcript: Q2 2025


Harrow Announces Second-Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 9 months ago

Harrow Announces Second-Quarter 2025 Financial Results


Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 1 year ago

Harrow to Present at Two Investor Conferences in May


Harrow Earnings Call Transcript: Q1 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings Call Transcript: Q1 2025


Harrow Announces First-Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 1 year ago

Harrow Announces First-Quarter 2025 Financial Results


NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 24, 2025, 10:00 AM EDT - 1 year ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.


Harrow Earnings Call Transcript: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings Call Transcript: Q4 2024


Harrow Launches VEVYE® Access for All

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Harrow Launches VEVYE® Access for All


Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Jan 7, 2025, 7:00 AM EST - 1 year ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer


Finnish_boy
Finnish_boy May. 13 at 10:11 AM
$HROW Shit happens. They should have been more strict about pricing already in Q1. Crazy buy right now. Bottom $25-29, no idea when/where. Some people can be worried bc they have no idea what is ahead and why the problems were meaningless.
0 · Reply
Finnish_boy
Finnish_boy May. 13 at 9:08 AM
$HROW $30->$200 is 550% in 4 years.
0 · Reply
Finnish_boy
Finnish_boy May. 13 at 9:07 AM
$HROW My PT $100 2027 and PT $200 by the year end of 2029. $400-500 PTs are bs imo. Revenue growth and operational leverage huge but not crazy.
0 · Reply
Finnish_boy
Finnish_boy May. 13 at 6:38 AM
$HROW Amazing write-up. Brilliant. Read it and realize that even mgt keeps missing guidances, you will win tons of money next years. https://mvcinvesting.substack.com/p/harrow-hrow-q1-2026-earnings-review
0 · Reply
Finnish_boy
Finnish_boy May. 13 at 6:37 AM
$HROW At the weekly level of 200 MA ($25.5), I think there will be a turnaround like at the beginning of 2024 and then we will see in a year that it was a good place to buy again. Of course, anything can happen, but I have a very strong feeling that the stock will hit $100 within 1-2 years.
1 · Reply
S144
S144 May. 13 at 5:06 AM
$HROW At $29 it is a real bargain. I would say: it is a buy. Let's say: if it recovers fully after Q2 results one could gain +38% in just 3 months.
1 · Reply
Dbarnyard
Dbarnyard May. 13 at 2:22 AM
$HROW Some people made fun of me when I suggested that the stock price of $ETON would overtake HROW. Perhaps the market caps will cross soon as well. Then those people can apologize to me 😄
0 · Reply
bitdix66
bitdix66 May. 12 at 9:54 PM
$HROW If you've been a shareholder for awhile (since 2021 myself) you know just how volatile this stock is. I've become "numb" to these massive drawdowns. I am still long, but... I do not believe they will achieve the $250 million quarter in Q4 2027. I think it is more reasonable in 2030, and anytime before then is a bonus. ---2030 @ $1 billion--- $1B revenue * 25% Net Income = $250M profit * 15 P/E = $3.75B MC / 40 million shares = $93/sh That's a 3x from here in 4 years (30% IRR). They may also have higher net margins than 25%. Pat Sullivan (Chief Commercial Officer) who was on the call also has his comp package tied to the $230M in branded segment per quarter. Source: https://investors.harrow.com/static-files/bdf5e5d6-0728-4a1d-9302-e70bc9dfeb14 Mark and Andrew have PSUs if the stock reaches $100. These guys do not want to fail. They have consistently pivoted and changed course to success over the past 5 years I've been following these guys (anyone remember Visionology and MAQ-100?). But they need to figure out the pricing strategy for Vevye.
5 · Reply
SelfMafia
SelfMafia May. 12 at 9:03 PM
$HROW Jonah Lupton Special
0 · Reply
Hpad06
Hpad06 May. 12 at 8:42 PM
$HROW for this growth, no reason to panic, buy the dip
1 · Reply
Tennis_4567
Tennis_4567 May. 12 at 8:07 PM
$HROW i think this will bottom out in the $25 area. what a goddam shame we are here. We would be trading at $75 right now if management undertstood setting expectations and providing guidance.
1 · Reply
cloudhedge
cloudhedge May. 12 at 7:56 PM
$HROW is a long-term holding with earnings volatility and sentiment swings. It has built a U.S. ophthalmic platform with the largest prescription eye-care portfolio in North America, now in a scaling phase. VEVYE targets ~16M dry eye patients, IHEEZO over 14M annual procedures, with low penetration. Q1: VEVYE +25%, IHEEZO +18%, TRIESENCE +136%, but total revenue -8%, showing a volume–price mismatch. Early commercialization: share gained via subsidies. Patients refill ~9 times/year, with improving net pricing. ~30% ASP uplift from Q2 is an early signal. The $2.5B quarterly target may shift toward 2028. Growth supported by BYOOVIZ, OPUVIZ, and G-MELT. Long term, it becomes a compounding model with patents through 2039, strong refill economics, and M&A capacity, supported by aging demand. Inflection likely in H2. Follow me 👉 @cloudhedge for real-time updates and everything. Let’s make moves!
0 · Reply
kingeboue
kingeboue May. 12 at 7:42 PM
$HROW this is brutal atm
0 · Reply
flash9875
flash9875 May. 12 at 7:39 PM
$HROW nothing fun about this...
0 · Reply
Bondra
Bondra May. 12 at 7:34 PM
$HROW Dog stock with dog MGMT
0 · Reply
AceBeck
AceBeck May. 12 at 7:30 PM
$HROW Must say, this was brutal
0 · Reply
Finnish_boy
Finnish_boy May. 12 at 5:47 PM
$HROW Pretty sure Boll had typo on excel.. that's why guidance miss. Nothing to worry.
0 · Reply
AceBeck
AceBeck May. 12 at 4:42 PM
$HROW Wow
0 · Reply
sukit34
sukit34 May. 12 at 4:40 PM
$HROW it's like everyone forgets the seasonailty in the business. Go back and take a look at the market reaction to Q1 2025. This is a gift.
2 · Reply
Aombeus
Aombeus May. 12 at 4:18 PM
$HROW single digits incoming
1 · Reply
GilLew
GilLew May. 12 at 4:08 PM
$HROW healthcare tape tightening up buyers look patient near support
0 · Reply
Stacks_Edwards
Stacks_Edwards May. 12 at 3:49 PM
$HROW added here. 1500 shares total. Now we wait.
0 · Reply